BioNTech currently produces 8 million doses of its vaccine every three to seven days at the new Marburg facility that the company purchased from Novartis last fall.

BioNTech SE said Friday that the European Medicines Agency (EMA) has approved its Marburg facility in Germany for the manufacture of the COVID-19 vaccine drug substance, which would boost annual ...

This 11-min. time-lapse shows the final step of production: technicians at BioNTech’s Marburg complex filter the vaccine before pumping it into bulk packages ready for shipping to a filling and ...

BioNTech’s manufacturing facility in Marburg is a GMP-certified manufacturing facility. Good manufacturing practice (GMP) is a system of regulatory standards for ensuring that products are ...

The Marburg site is a “key factor” in the partners’ push to 2 billion doses, BioNTech said, and will be one of the largest mRNA manufacturing sites in Europe.

—BioNTech SE today announced that the European Medicines Agency approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. Due to optimized operational ...

BioNTech will invest 40 million euros ... [1/2] A view of BioNTech building in Marburg, Germany, February 2, 2023. REUTERS/Fabian Bimmer Purchase Licensing Rights, opens new tab.

(RTTNews) - BioNTech SE (BNTX) said the company's new BioNTech site will become one of the largest mRNA manufacturing sites in Europe with an annual production capacity of up to 750 million doses ...

Facility will become one of the largest mRNA manufacturing sites in Europe and the third site in the BioNTech manufacturing network in Germany expected to produce ...

Chancellor Olaf Scholz of Germany and the BioNTech founders Ugur Sahin and Özlem Türeci view a model of plasmid at the BioNTech plant in Marburg, Germany, in February.

MAINZ, GERMANY, February 10, 2021 (GLOBE NEWSWIRE) - We started the manufacturing process at the Marburg facility with the execution of the first ...